Annovis Bio, Inc. (ANVS)

Accolade Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	22.24	10.55	5.75	28.38	45.69	8.07
Cash & Short-Term Investments	22.24	10.55	5.75	28.38	45.69	8.07
Cash Growth	608.84%	83.36%	-79.72%	-37.89%	465.79%	434488.70%
Prepaid Expenses	4.49	0.37	0.04	0.1	0.07	0.04
Other Current Assets	0.01	3.01	4.41	7.54	0.24	0.01
Total Current Assets	26.74	13.93	10.21	36.02	46	8.12
Total Assets	26.74	13.93	10.21	36.02	46	8.12
Accounts Payable	1.37	2.31	1.29	3.96	0.69	0.34
Accrued Expenses	1.13	1.58	2.99	3.74	0.82	0.24
Total Current Liabilities	2.5	3.88	4.28	7.7	1.51	0.58
Other Long-Term Liabilities	0.18	0.74	13.68	-	-	-
Total Liabilities	2.68	4.62	17.96	7.7	1.51	0.58
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	164.44	144.16	102.51	82.38	73.22	21.78
Retained Earnings	-140.39	-134.85	-110.26	-54.05	-28.73	-14.24
Total Common Equity	24.05	9.31	-7.75	28.32	44.49	7.54
Shareholders' Equity	24.05	9.31	-7.75	28.32	44.49	7.54
Total Liabilities & Equity	26.74	13.93	10.21	36.02	46	8.12
Net Cash (Debt)	22.24	10.55	5.75	28.38	45.69	8.07
Net Cash Growth	608.84%	83.36%	-79.72%	-37.89%	465.79%	-
Net Cash Per Share	1.60	0.86	0.64	3.48	5.99	1.28
Filing Date Shares Outstanding	19.49	19.49	11.01	8.22	8.16	6.95
Total Common Shares Outstanding	19.49	14.14	10.52	8.16	8.1	6.89
Working Capital	24.23	10.04	5.93	28.32	44.49	7.54
Book Value Per Share	1.23	0.66	-0.74	3.47	5.49	1.09
Tangible Book Value	24.05	9.31	-7.75	28.32	44.49	7.54
Tangible Book Value Per Share	1.23	0.66	-0.74	3.47	5.49	1.09

Updated Mar 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q